Table 4

HRs for outcomes with aspirin treatment compared with no aspirin treatment at Cox regression, by level of 5-year CVD risk, in 18 646 patients with type 2 diabetes followed for 4 years

	Patients N	Events N (%)	Events/1000 person-years	HR*(95% CI)	p Value
Non-fatal/fatal CVD
5-year CVD risk <15%	15296	593 (3.9)	10.8	1.07 (0.88 to 1.30)	0.5
5-year CVD risk >15%	3350	410 (12.2)	34.9	1.09 (0.88 to 1.35)	0.4
Fatal CVD
5-year CVD risk <15%	15296	89 (0.6)	1.6	0.83 (0.51 to 1.36)	0.5
5-year CVD risk >15%	3350	116 (3.5)	9.9	0.86 (0.57 to 1.28)	0.5
Non-fatal/fatal CHD
5-year CVD risk <15%	15296	409 (2.7)	7.5	1.21 (0.96 to 1.51)	0.1
5-year CVD risk >15%	3350	289 (8.6)	25.2	1.18 (0.92 to 1.51)	0.2
Fatal CHD
5-year CVD risk <15%	15296	74 (0.5)	1.3	0.73 (0.42 to 1.28)	0.3
5-year CVD risk >15%	3350	102 (3.0)	8.7	0.85 (0.55 to 1.30)	0.5
Non-fatal/fatal stroke
5-year CVD risk <15%	15296	200 (1.3)	3.6	0.83 (0.59 to 1.17)	0.3
5-year CVD risk >15%	3350	138 (4.1)	11.8	1.03 (0.71 to 1.50)	0.9
Fatal stroke
5-year CVD risk <15%	15296	15 (0.1)	0.3	1.45 (0.49 to 4.31)	0.5
5-year CVD risk >15%	3350	18 (0.5)	1.5	1.09 (0.40 to 2.95)	0.8
Total mortality
5-year CVD risk <15%	15296	370 (2.4)	6.7	0.94 (0.74 to 1.20)	0.6
5-year CVD risk >15%	3350	285 (8.5)	24.3	0.88 (0.68 to 1.14)	0.3

*Adjusted by stratification with deciles of a propensity score including the covariates age, sex, diabetes duration, previous hospitalisation, type of hypoglycaemic treatment, HbA1c, smoking, BMI, systolic blood pressure, ratio total-to-HDL cholesterol, albuminuria >20 µg/min, antihypertensive drugs, statins, other lipid lowering drugs, oestrogen and multidose dispensation. Sex and HbA1c were also added as covariates.
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein.